Divi's Laboratories Q2 profit rises 64% as custom synthesis business advances
Divi's Laboratories reported Q2 profit up 64% year on year and total income up 32%, while keeping its revenue growth and capex outlook.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Divi's Laboratories reported that second-quarter profit after tax rose 64% from a year earlier, while total income climbed 32%. According to TradingView, which relied on an AI-generated summary, standalone revenue in constant currency grew 17% in the first half.
Management still expects double-digit revenue growth. Annual capital spending is planned at about INR 2,000 crore, plus or minus 20%, with the focus on custom synthesis and capacity expansion.
why it matters
For investors in the Indian pharma sector, these figures serve as a gauge of demand for contract synthesis services. Strong profit growth and a clear investment plan usually reduce uncertainty around the stock, though one company's results rarely move the wider market.
market impact
Divi's shares: strong profit and a clear spending plan support interest in the stock
- Divi's Laboratories shares pressure up — profit growth and a confirmed spending plan support interest in the stock
tags
instruments
sources
- DIVISLAB: Q2 PAT rose 64% YoY as custom synthesis and capacity investment advanced — TradingView, 7 November 2026 at 11:26 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗